Breakdown | ||||
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
18.00K | 286.00K | 441.00K | 0.00 | 0.00 | Gross Profit |
18.00K | 229.00K | 242.00K | -550.00K | -54.35K | EBIT |
-28.51M | -27.27M | -33.41M | -59.18M | -34.60M | EBITDA |
-28.15M | -26.97M | -33.21M | -58.63M | -34.42M | Net Income Common Stockholders |
-29.04M | -27.27M | -31.36M | -52.17M | -33.92M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
190.00K | 458.00K | 11.66M | 28.27M | 12.11M | Total Assets |
1.80M | 4.11M | 15.52M | 30.39M | 14.22M | Total Debt |
452.00K | 765.00K | 656.00K | 314.00K | 723.42K | Net Debt |
262.00K | 408.00K | -11.00M | -27.95M | -11.39M | Total Liabilities |
4.68M | 3.71M | 2.95M | 5.11M | 2.34M | Stockholders Equity |
-2.91M | 418.00K | 12.35M | 24.48M | 11.36M |
Cash Flow | Free Cash Flow | |||
-17.50M | -21.87M | -26.94M | -26.69M | -15.77M | Operating Cash Flow |
-17.31M | -21.70M | -26.40M | -26.60M | -15.48M | Investing Cash Flow |
-186.00K | -168.00K | -542.00K | -87.00K | -285.93K | Financing Cash Flow |
17.33M | 10.57M | 10.33M | 42.85M | 23.43M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $5.28B | 3.75 | -42.72% | 2.86% | 17.70% | 2.03% | |
46 Neutral | $16.08M | ― | -266.25% | ― | 8.91% | 70.18% | |
42 Neutral | $12.25M | ― | -53.65% | ― | -88.70% | -3.48% | |
40 Underperform | $14.08M | ― | -499.57% | ― | 22.15% | ― | |
34 Underperform | $24.98M | ― | 5400.35% | ― | 122.22% | 79.08% | |
34 Underperform | $12.86M | ― | 110.26% | ― | -2.99% | 59.87% |
BioSig Technologies held its Annual Meeting where four key proposals were submitted to stockholders for voting. The proposals included electing five directors to the board, approving a reverse stock split, increasing shares under the Incentive Plan, and ratifying Marcum LLP as the independent accounting firm. The votes resulted in the election of directors, approval of the reverse stock split and Incentive Plan Amendment, and ratification of the accounting firm, reflecting shareholder support for the company’s strategic decisions.